About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multi-national specialty pharmaceutical company that develops and markets prescription and nonprescription pharmaceutical products that make a meaningful difference in patients' lives. Valeant is focused on the neurology and dermatology therapeutic areas primarily in the United States, Canada, Mexico, Brazil, Central and Eastern Europe and Australia.

In September 2010, Valeant Pharmaceuticals International and Biovail Corporation merged to become one company. This compelling combination is expected to create tremendous value for stockholders of both companies as the businesses benefit from cost savings, greater scale, and enhanced financial strength and flexibility. The new combined company also completed a name change to Valeant Pharmaceuticals International, Inc. and our shares now trade on both the New York Stock Exchange and the Toronto Stock Exchange under the ticker symbol "VRX".

Valeant's strategy is to focus the business on core geographies and therapeutic classes, manage pipeline assets through strategic partnerships with other pharmaceutical companies and deploy cash with an appropriate mix of selective acquisitions, share buybacks and debt repurchases. Our leveraged research and development model is one key element to this business strategy and will allow us to progress development programs to drive future commercial growth, while minimizing our research and development expense.

Based in Mississauga, Ontario, Canada, Valeant employs approximately 5,000 people worldwide.